Want to see MPLT full AI Analyst Report?
MapLight Therapeutics, Inc. (MPLT) Stock Statistics & Valuation Metrics
Total Valuation
MapLight Therapeutics, Inc. has a market cap or net worth of $421.26M. The enterprise value is $1.33B.
- Market Cap
- $421.26M
- Enterprise Value
- $1.33B
Share Statistics
MapLight Therapeutics, Inc. has 55,575,718 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 55,575,718
- Owned by Insiders
- 51.44%
- Owned by Institutions
- 11.98%
Financial Efficiency
MapLight Therapeutics, Inc.’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -36.43%.
- Return on Equity (ROE)
- -0.35
- Return on Assets (ROA)
- -0.34
- Return on Invested Capital (ROIC)
- -36.43%
- Return on Capital Employed (ROCE)
- -0.36
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.21M
- Employee Count
- 133
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of MapLight Therapeutics, Inc. is -1.46. MapLight Therapeutics, Inc.’s PEG ratio is 0.02.
- PE Ratio
- -1.46
- PS Ratio
- 0.00
- PB Ratio
- 0.99
- Price to FCF
- -1.84
- Price to Operating Cash Flow
- -1.97
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, MapLight Therapeutics, Inc. had revenue of 0 and earned -161.15M in profits. Earnings per share was -3.66.
- Revenue
- 0
- Gross Profit
- -578.00K
- Operating Income
- -169.08M
- Pretax Income
- -161.15M
- Net Income
- -161.15M
- EBITDA
- -160.57M
- Earnings Per Share (EPS)
- -3.66
Cash Flow
In the last 12 months, operating cash flow was -174.67M and capital expenditures -453,000, giving a free cash flow of -175.12M billion.
- Operating Cash Flow
- -174.67M
- Free Cash Flow
- -175.12M
- Free Cash Flow per Share
- -3.85
Dividends & Yields
MapLight Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -54.21%
- Earnings Yield
- -66.74%
Stock Price Statistics
- Beta
- 0.97
- 52-Week Price Change
- -58.74%
- 50-Day Moving Average
- 10.51
- 200-Day Moving Average
- 20.61
- Relative Strength Index (RSI)
- 31.46
- Average Volume (3m)
- 508.95K
Important Dates
MapLight Therapeutics, Inc. upcoming earnings date is ―, After Close (Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
MapLight Therapeutics, Inc. as a current ratio of 20.01, with Debt / Equity ratio of 1.27%
- Current Ratio
- 20.01
- Quick Ratio
- 20.01
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.25
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, MapLight Therapeutics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
MapLight Therapeutics, Inc. EV to EBITDA ratio is -1.09, with an EV/FCF ratio of -1.45.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.09
- EV to Free Cash Flow
- -1.45
- EV to Operating Cash Flow
- -1.45
Balance Sheet
MapLight Therapeutics, Inc. has $304.73M in cash and marketable securities with $1.99M in debt, giving a net cash position of $302.74M billion.
- Cash & Marketable Securities
- $304.73M
- Total Debt
- $1.99M
- Net Cash
- $302.74M
- Net Cash Per Share
- $5.45
- Tangible Book Value Per Share
- $7.67
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for MapLight Therapeutics, Inc. is $26.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $26.80
- Price Target Upside
- 253.56% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 1
- AI Score
- 51
